Table 3.

Relationship between CDK7, Cyclin H, and MAT1 expression and breast cancer subtypes

CDK7Cyclin HMAT1
LowHighPLowHighPLowHighP
Variable(0–160)(161–300)(χ2)(0–194)(195–300)(χ2)(0–179)(180–300)(χ2)
ER
 Negative87 (32.2)148 (22.2)0.001194 (32.1)117 (19.4)<0.001151 (34.2)93 (20.3)<0.001
 Positive183 (67.8)520 (77.8)(10.4)410 (67.9)486 (80.6)(25.5)291 (65.8)365 (79.7)(21.9)
PGR
 Negative128 (49.2)248 (38.3)0.002292 (49.6)191 (33)<0.001214 (49.7)157 (35.7)<0.001
 Positive132 (50.8)400 (61.7)(9.2)297 (50.4)388 (67)(33.1)217 (50.3)283 (64.3)(17.4)
ER/PGR status
 ER+/PGR+132 (50.8)400 (61.7)0.003295 (50.3)387 (67.1)<0.001217 (50.3)282 (64.4)<0.001
 ER+/PGR46 (17.7)108 (16.7)(11.4)104 (17.7)80 (13.9)(35.4)68 (15.8)71 (16.2)(25.6)
 ER/PGR82 (31.5)140 (21.6)187 (31.9)110 (19.1)146 (33.9)85 (19.4)
AR
 Negative125 (52.7)199 (33.2)<0.001249 (46.5)155 (28.9)<0.001179 (46.9)120 (29.3)<0.001
 Positive112 (47.3)400 (66.8)(27.3)287 (53.5)381 (71.1)(35.1)203 (53.1)290 (70.7)(26.0)
FOXA1
 Negative67 (34.7)209 (48.5)0.001154 (37.6)199 (52.5)<0.001119 (36.1)150 (52.8)<0.001
 Positive (≥10)126 (65.3)222 (51.5)(10.3)256 (62.4)180 (47.5)(17.8)211 (63.9)134 (47.2)(17.4)
GATA3
 Negative/low (<60)154 (87.5)277 (71.9)<0.001310 (83.8)229 (70.2)<0.001245 (86)177 (67.3)<0.001
 Positive (≥60)22 (12.5)108 (28.1)(16.4)60 (16.2)97 (29.8)(18.2)40 (14)86 (32.7)(26.9)
HER2
 Negative212 (81.2)566 (87.5)0.015506 (86.3)500 (86.8)NS350 (81.4)394 (90)<0.001
 Positive49 (18.8)81 (12.5)(5.9)80 (13.7)76 (13.2)80 (18.6)44 (10)(13.0)
TN
 Non-TN207 (87.7)554 (84.6)0.033453 (76.3)523 (88.5)<0.001329 (76.3)390 (87.1)<0.001
 TN56 (21.3)101 (15.4)(4.6)141 (23.7)68 (11.5)(30.5)102 (23.7)58 (12.9)(16.9)